• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Zelluna

Less than 1K followers

ZLNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
9.9.
2026

Extraordinary general meeting '26

5.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Regulatory press release20.08.2026 klo 08.00

Zelluna ASA: Second Quarter 2026 results

Zelluna
Regulatory press release17.08.2026 klo 14.11

Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101

Zelluna
Regulatory press release17.08.2026 klo 11.13

Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down  

Zelluna

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release17.08.2026 klo 08.45

Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down

Zelluna
Regulatory press release13.08.2026 klo 13.00

Zelluna ASA: Invitation to Second Quarter 2026 Results Webcast Presentation

Zelluna
Regulatory press release10.08.2026 klo 10.46

Zelluna ASA: New share capital registered

Zelluna
Regulatory press release06.08.2026 klo 13.42

Zelluna ASA: Disclosure of large shareholding

Zelluna
Regulatory press release06.08.2026 klo 13.42

Zelluna ASA: Disclosure of large shareholding

Zelluna
Regulatory press release04.08.2026 klo 18.23

Zelluna ASA: Disclosure of large shareholding

Zelluna
Regulatory press release04.08.2026 klo 18.23

Zelluna ASA: Disclosure of large shareholding

Zelluna
Regulatory press release04.08.2026 klo 17.53

Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement

Zelluna
Regulatory press release13.07.2026 klo 18.08

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

Zelluna
Regulatory press release02.07.2026 klo 15.33

Zelluna ASA - Grant of Share Options

Zelluna
Regulatory press release30.06.2026 klo 11.12

ZLNA: Zelluna ASA awarded NOK 16 million Research Council of Norway grant

Zelluna
Regulatory press release30.06.2026 klo 11.12

Zelluna ASA awarded NOK 16 million Research Council of Norway grant

Zelluna
Regulatory press release29.06.2026 klo 14.03

Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement

Zelluna
Regulatory press release29.06.2026 klo 10.59

Zelluna ASA: New share capital registered

Zelluna
Regulatory press release29.06.2026 klo 09.30

ZLNA: Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

Zelluna
Regulatory press release29.06.2026 klo 09.30

Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities

Zelluna
Regulatory press release26.06.2026 klo 17.40

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Zelluna